Brokerages expect that Verrica Pharmaceuticals Inc (NASDAQ:VRCA) will report earnings per share (EPS) of ($0.26) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Verrica Pharmaceuticals’ earnings. The company is expected to report its next quarterly earnings results on Wednesday, February 6th.

On average, analysts expect that Verrica Pharmaceuticals will report full year earnings of ($1.09) per share for the current fiscal year, with EPS estimates ranging from ($1.42) to ($0.75). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.08) per share, with EPS estimates ranging from ($1.25) to ($0.90). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Verrica Pharmaceuticals.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its earnings results on Wednesday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.03).

Separately, Zacks Investment Research lowered shares of Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 20th.

NASDAQ:VRCA opened at $10.25 on Monday. Verrica Pharmaceuticals has a 12-month low of $10.03 and a 12-month high of $23.29.

In other news, Director Paul B. Manning bought 70,200 shares of Verrica Pharmaceuticals stock in a transaction on Tuesday, November 13th. The shares were bought at an average cost of $14.15 per share, for a total transaction of $993,330.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Linda Palczuk bought 2,500 shares of Verrica Pharmaceuticals stock in a transaction on Monday, September 17th. The stock was purchased at an average price of $16.52 per share, for a total transaction of $41,300.00. The disclosure for this purchase can be found here.

A number of large investors have recently added to or reduced their stakes in VRCA. Kornitzer Capital Management Inc. KS purchased a new position in Verrica Pharmaceuticals in the 2nd quarter valued at about $2,905,000. Dean Capital Investments Management LLC purchased a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth about $676,000. Asymmetry Capital Management L.P. purchased a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth about $1,184,000. FMR LLC purchased a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth about $21,703,000. Finally, Fosun International Ltd purchased a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth about $15,705,000. Institutional investors own 32.07% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.

Featured Story: Cost of Equity For A Business, Investors

Get a free copy of the Zacks research report on Verrica Pharmaceuticals (VRCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.